Andy GÃ¶bel

List of Publications by Year
in descending order

24 papers	507 citations	759233 12 h-index	677142 22 g-index
24 all docs	24 docs citations	24 times ranked	714 citing authors

#	Article	IF	Citations
1	Cholesterol and beyond - The role of the mevalonate pathway in cancer biology. Biochimica Et Biophysica Acta: Reviews on Cancer, 2020, 1873, 188351.	7.4	87
2	Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells. Cell Death and Disease, 2019, 10, 91.	6.3	66
3	Combined inhibition of the mevalonate pathway with statins and zoledronic acid potentiates their anti-tumor effects in human breast cancer cells. Cancer Letters, 2016, 375, 162-171.	7.2	39
4	Dickkopf-1 as a mediator and novel target in malignant bone disease. Cancer Letters, 2014, 346, 172-177.	7.2	36
5	Dickkopf-1 is regulated by the mevalonate pathway in breast cancer. Breast Cancer Research, 2014, 16, R20.	5.0	32
6	Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer. Clinical Cancer Research, 2019, 25, 1369-1378.	7.0	28
7	Evolving functions of Dickkopf-1 in cancer and immunity. Cancer Letters, 2020, 482, 1-7.	7.2	25
8	Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer. BMC Cancer, 2020, 20, 703.	2.6	22
9	Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer. Breast Cancer Research, 2017, 19, 92.	5.0	21
10	Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. Breast Cancer Research and Treatment, 2015, 154, 623-631.	2.5	20
11	The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone. International Journal of Molecular Sciences, 2021, 22, 5078.	4.1	20
12	Zoledronic acid and atorvastatin inhibit Î±vÎ²3-mediated adhesion of breast cancer cells. Journal of Bone Oncology, 2014, 3, 10-17.	2.4	16
13	High serum levels of periostin are associated with a poor survival in breast cancer. Breast Cancer Research and Treatment, 2020, 180, 515-524.	2.5	15
14	P38 regulates the Wnt inhibitor Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2015, 466, 728-732.	2.1	11
15	Regulation of VEGF by mevalonate pathway inhibition in breast cancer. Journal of Bone Oncology, 2013, 2, 110-115.	2.4	10
16	Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3122-3133.	3.6	10
17	Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin. Journal of Bone Oncology, 2014, 3, 18-24.	2.4	9
18	From Pharmacology to Physiology: Endocrine Functions of Î¼-Opioid Receptor Networks. Trends in Endocrinology and Metabolism, 2021, 32, 306-319.	7.1	9

#	Article	IF	Citations
19	Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients. Breast Cancer Research and Treatment, 2017, 164, 737-743.	2.5	8
20	Dorsomorphin: A novel inhibitor of Dickkopf-1 in breast cancer. Biochemical and Biophysical Research Communications, 2020, 524, 360-365.	2.1	5
21	Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity. Cancers, 2022, 14, 603.	3.7	5
22	Bone Metastases: From Mechanisms to Treatment. Seminars in Oncology Nursing, 2022, , 151277.	1.5	5
23	The mevalonate pathway in breast cancer biology. Cancer Letters, 2022, 542, 215761.	7.2	5
24	Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients. Journal of Bone Oncology, 2019, 16, 100237.	2.4	3